Certara Logo White Background.png
Certara to Report First Quarter 2022 Financial Results on May 5th, 2022
April 20, 2022 08:00 ET | Certara
PRINCETON, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of...
Certara Logo White Background.png
Certara Reports Fourth Quarter and Full Year 2021 Financial Results
March 01, 2022 16:15 ET | Certara
PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2021...
Certara Logo White Background.png
U.S. FDA Licenses Certara’s Immunogenicity Simulator
February 23, 2022 16:30 ET | Certara
PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has licensed...
Certara Logo White Background.png
在过去8年中,美国FDA每一年批准的新药中90%来自Certara的客户
February 22, 2022 01:26 ET | Certara USA, Inc.
新泽西州普林斯顿 , Feb. 22, 2022 (GLOBE NEWSWIRE) -- 全球生物模拟领域的领军企业Certara, Inc.(纳斯达克股票代码:CERT),今日宣布在2021年美国食品药品监督管理局 (FDA) 药品审评和研究中心 (CDER)...
Certara Logo White Background.png
Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year
February 15, 2022 16:30 ET | Certara
PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug...
Certara Logo White Background.png
Certara to Report Fourth Quarter and Full Year 2021 Financial Results on March 1st, 2022
February 08, 2022 16:30 ET | Certara
PRINCETON, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and...
Certara Logo White Background.png
Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions
December 21, 2021 08:00 ET | Certara
PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that the U.S. Food and Drug Administration (FDA) has renewed and...
Certara Logo White Background.png
Certara Announces Release of Pinnacle 21 Enterprise Software
December 13, 2021 08:00 ET | Certara
PRINCETON, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the feature release of Pinnacle 21 Enterprise 5.1.0, which updates...
Certara Logo White Background.png
Certara to Host Investor Day on December 15, 2021
December 08, 2021 17:00 ET | Certara
PRINCETON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM...
Certara Logo White Background.png
Certara 宣布两项重要人事任命,中国团队发展壮大
December 03, 2021 06:42 ET | Certara USA, Inc.
新泽西州普林斯顿, Dec. 03, 2021 (GLOBE NEWSWIRE) --  日快讯。全球生物模拟科技行业巨头 Certara, Inc.(纳斯达克股票代码:CERT)今日宣布任命李改玲博士为高级副总裁兼中国区首席科学官,并任命张静为监管科学业务发展部总监。Certara 上海办事处的这两项人事任命旨在为中国生物制药公司提供更多本地支持,将进一步推动公司在全球不断向前发展。 ...